A New Chapter for Livestock Disease Control
South Africa is taking steps to expand domestic production of a locally developed foot-and-mouth disease (FMD) vaccine, with the government and Agricultural Research Council agreeing to allow qualifying private companies to use the council's intellectual property under conditional licensing arrangements.
The announcement was made by Agriculture Minister Willie Aucamp on 21 September 2026.
The objective is to increase manufacturing capacity and overcome constraints that have limited the Agricultural Research Council's ability to produce the vaccine at scale.
Why FMD Matters
Foot-and-mouth disease is one of the most economically important livestock diseases affecting international trade.
An outbreak can disrupt livestock movement, affect market access and place significant pressure on farmers, veterinary authorities and governments.
For cattle producers in particular, disease control is not simply an animal-health issue.
It can become a trade issue.
A country that struggles to control outbreaks can face restrictions that affect the movement and sale of livestock and livestock products.
Bringing the Private Sector Into Vaccine Production
The South African government's decision is significant because it moves the conversation from vaccine research to manufacturing scale.
According to the government, the Agricultural Research Council's vaccine is effective against domestic FMD strains and requires a single annual administration, but the council has faced manufacturing constraints that have prevented production at the required scale.
Under the proposed approach, qualifying local or international companies would manufacture the vaccine under conditional intellectual-property licensing agreements with the ARC.
What This Could Mean for Farmers
Sponsored
For livestock farmers, vaccine availability is one part of a much wider disease-control system.
Effective disease management also depends on surveillance, veterinary services, movement controls, farmer awareness, laboratory capacity and rapid response when outbreaks occur.
But reliable access to vaccines can strengthen that system.
If production can be expanded successfully, South Africa could have greater capacity to respond to domestic disease risks while reducing pressure caused by limited manufacturing capacity.
Biosecurity Becomes an Investment Issue
The development also highlights an important change in African agriculture.
Animal health is increasingly becoming an investment issue.
A modern livestock value chain requires not only better genetics and feed but also reliable disease surveillance, vaccines, diagnostics and traceability.
For meat producers and exporters, these systems can determine whether animals and products can move into premium markets.
A Test for Public-Private Cooperation
The next stage will be implementation.
Licensing intellectual property is one step. Building or expanding manufacturing facilities, maintaining quality standards and producing sufficient volumes will determine whether the policy delivers its intended impact.
The South African government says private-sector participation is intended to strengthen national biosecurity and food supply chains.
If successful, the initiative could offer a model for other African countries seeking to strengthen local capacity for animal-health products.
For South Africa's livestock sector, the message is increasingly clear:
Animal health is not just about treating disease after an outbreak. It is about building the production systems, science and manufacturing capacity needed to prevent disruption in the first place.
